- Kopetz, S., Yoshino, T., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., Beyzarov, E., Zhang, X., Ferrier, G., Zhang, X., & Tabernero, J. (2025). The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: A plain language summary. Future Oncology, 21(13), 1541-1552. https://doi.org/10.1080/14796694.2025.2491290
The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: A plain language summary
on 22 de setembre de 2025
with No hi ha comentaris
Deixa un comentari